A Phase 2 Open Label Study of REC-4881 in Participants with Unresectable Locally Advanced or Metastatic Cancer with AXIN1 or APC Mutation

Brief description of study

This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatment of participants with unresectable locally advanced or metastatic solid tumors with AXIN1 or APC mutation.


Clinical Study Identifier: s23-01082
ClinicalTrials.gov Identifier: NCT06005974
Principal Investigator: Nina Beri.
Other Investigators: Nila Theresa De La Rosa, Joshua K Sabari, Samantha VanMaanen, Jessica Wang, Elaine Shum, Kristen Spencer, Scot Niglio, Keriann M Scavone, Kathleen M Madden, Nancy Chan, Douglas K Marks, Janice Mehnert, David R. Wise.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.